Midostaurin (PKC412)

Name: Midostaurin (PKC412)
Brand: Selleck Chemicals
SKU: S8064
Rating: 5 (23 reviews)

For research use only.

Catalog No.S8064 Synonyms: CGP 41251

23 publications

CAS No. 120685-11-2

Midostaurin (pkc412, CGP 41251) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Selleck's Midostaurin (PKC412) has been cited by 23 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0731-z

PubMed: 32015510 ( click the link to review the publication )

Eur J Med Chem, 2020, 193:112232

PubMed: 32199135 ( click the link to review the publication )

Transl Oncol, 2020, 1;13(4):100766

PubMed: 32247263 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-020-04114-z

PubMed: 32748108 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2341

PubMed: 32825035 ( click the link to review the publication )

Haematologica, 2020, haematol.2019.231944

PubMed: 32616529 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0832

PubMed: 31320594 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31270078 ( click the link to review the publication )

Cancer Lett, 2019, 445:34-44

PubMed: 30639533 ( click the link to review the publication )

Cell Commun Signal, 2019,

PubMed: 31484543 ( click the link to review the publication )

Oncogenesis, 2019, 8(8):39

PubMed: 31311917 ( click the link to review the publication )

Blood, 2018, 25;131(4):426-438

PubMed: 29187377 ( click the link to review the publication )

Leukemia, 2018, 32(1):139-148

PubMed: 28663576 ( click the link to review the publication )

Leukemia, 2018, 32(2):313-322

PubMed: 28895560 ( click the link to review the publication )

Cell Death Dis, 2018, 10(1):8

PubMed: 30584254 ( click the link to review the publication )

J Cell Physiol, 2018, 233(12):9437-9446

PubMed: 29968910 ( click the link to review the publication )

Oncotarget, 2018, 9(2):2320-2328

PubMed: 29416774 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35962-35973

PubMed: 30542510 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0183161

PubMed: 28817624 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Elife, 2014, 3

PubMed: 25531068 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description

Targets

PKCα ^[1] (Cell-free assay)	PKCγ ^[1] (Cell-free assay)	PKCβ1 ^[1] (Cell-free assay)	PKCβ2 ^[1] (Cell-free assay)	PPK ^[1] (Cell-free assay)	View More
22 nM	24 nM	30 nM	31 nM	38 nM	View More

In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. ^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human MV4-11 cells	MnnFR5l1d3SxeHnjbZR6KGG\|c3H5	MWS3NkBp	MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0yOiCwTR?=	NFPuZnoyQTZ3NESwPC=>
RS4-11 cells	NUfkPXFTTnWwY4Tpc44h[XO\|YYm=	MkK0NkBp	MXrJcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFKVND2xNUBk\WyuczDh[pRmeiB{IHjyd{BjgSCnbHXjeJJw[2inbXnseY1qdmW\|Y3XuZ4Uh[XO\|YYmsJGlEPTB;MUOgcm0>	MYixPVY2PDRyOB?=
CGTH-W-1 cell	M4D3U2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MknGTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQzNjZ3IN88US=>	NEfYbIxUSU6JRWK=
SW982 cell	NWTES3NpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4HWZmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20OU42QCEQvF2=	MlTDV2FPT0WU
human EoL-1-cell cell	MkjhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkPITY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTJwMEigcm0>	NIjpRYlUSU6JRWK=
MOLM-13 cells	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3\6dlczKGh?	MYrJcohq[mm2aX;uJI9nKE[OVEOgTXRFKGindHXyc5p6\2:3czDteZRidnRiaX6gbJVu[W5iTV;MUU0yOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTB;MD6wOVUh\|ryP	MXKyOlA5OTB{Mx?=
KASUMI-1 cell	M2fvdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHLiTW1KdmirYnn0bY9vKG:oIHj1cYFvKEuDU2XNTU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yNkCxOkDPxE1?	MX\TRW5ITVJ?
NCI-H1755 cell	NEnXSpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmLMTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3OVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MkezJO69VQ>?	M1rqTXNCVkeHUh?=
human MES-SA cell	NUfWenppT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHfEfJlKdmirYnn0bY9vKG:oIHj1cYFvKE2HUz3TRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODd3NESg{txO	NG\KO2pUSU6JRWK=
human HCC1395 cell	NFPpcIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkftTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzM{m1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDR{ODFOwG0>	MlPWV2FPT0WU
human D-336MG cell	M3\n[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmDwTY5pcWKrdHnvckBw\iCqdX3hckBFNTN\|Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDd3NDFOwG0>	MnW0V2FPT0WU
CHP-212 cell	NHX3ZXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkXGTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDd5MzFOwG0>	MUTTRW5ITVJ?
human KM12 cell	NGHjO5VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGtOOTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkC5Nlc2KM7:TR?=	M33ZOnNCVkeHUh?=
A204 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEDGb5RKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExODV{IN88US=>	NFX6d41USU6JRWK=
CAL-51 cell	M2TBVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnnqTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExPzB7IN88US=>	NIPzT3pUSU6JRWK=
human A431 cell	MoXKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXzwV\|JMUW6qaXLpeIlwdiCxZjDoeY1idiCDNEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTJzNjFOwG0>	MlX0V2FPT0WU
NCI-H650 cell	MnjJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlvaTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF5MEig{txO	NGP1WZVUSU6JRWK=
A427 cell	M4L4S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIrDfmhKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyQTF6IN88US=>	MmH1V2FPT0WU
human 769-P cell	M1vJcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF3lZnlKdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjB6MjFOwG0>	M3;NSnNCVkeHUh?=
SW1710 cell	NYrTdFd2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVz3c5NNUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF\|M{G2JO69VQ>?	MYHTRW5ITVJ?
human H4 cell	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFj6c4hKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6xN\|k3OyEQvF2=	NFHJd5hUSU6JRWK=
HT-1080 cell	NEWxWZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{HBT2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV7OEKg{txO	MWHTRW5ITVJ?
human PANC-03-27 cell	NGjCTJpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWfxV5ZvUW6qaXLpeIlwdiCxZjDoeY1idiCSQV7DMVA{NTJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6xOlAzKM7:TR?=	M3HVe3NCVkeHUh?=
A375 cells	NUX2XId5S3m2b4TvfIlkcXS7IHHzd4F6	MUO3NkBp	M{K5OHRwgGmlaYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3icJVmKGG\|c3H5MEBKSzVyPUCuNVgh\|ryP	MWmxPVY2PDRyOB?=
human HOP-62 cell	M{fwZ2Z2dmO2aX;uJIF{e2G7		Mlj5TY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE5ODd\|IN88US=>	NU\0VWlxW0GQR1XS
human U031 cell	NYPBTYxMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXHJcohq[mm2aX;uJI9nKGi3bXHuJHUxOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG5Olk5KM7:TR?=	NGPXdnNUSU6JRWK=
mouse BAF3 cells	MkSxVJJwdGmoZYLheIlwdiCjc4PhfS=>		MoLFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IITyZY5{\m:{bXXkJJdqfGhiWl7GNVk5NU[JRmKxJINwdnO2coXjeEwhUUN3ME2wMlIh\|ryP	NGnveHQzOTl\|NkW0Ni=>
human G-402 cell	NIC0[I9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGXCSW1KdmirYnn0bY9vKG:oIHj1cYFvKEdvNECyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zODJ3MzFOwG0>	M3;sS3NCVkeHUh?=
human G-361 cell	NIXROI9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUTJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6yNFg2OyEQvF2=	NUjTcWpuW0GQR1XS
NCI-H810 cell	NY[0WXBpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KOEGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOTB{NzFOwG0>	NHTwS4hUSU6JRWK=
NCI-H2030 cell	NITKfm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX33Uo1{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKzNFA3KM7:TR?=	MVrTRW5ITVJ?
human HCT-116 cell	Ml\tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1G0VWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN3Nkig{txO	Ml\FV2FPT0WU
human SNU-423 cell	MkfSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlPKTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvNEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzZ3NzFOwG0>	M{T3Z3NCVkeHUh?=
human SCC-4 cell	NIKzXppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWTJcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6yN\|k3PyEQvF2=	M{XsOnNCVkeHUh?=
human SW48 cell	M4fIcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1HrXWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNlY3QCEQvF2=	MWTTRW5ITVJ?
human SF295 cell	M1W2ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NY\uV\|M1UW6qaXLpeIlwdiCxZjDoeY1idiCVRkK5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjd{NUeg{txO	NUP1[5JPW0GQR1XS
MDA-MB-231 cell	M3r3Tmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUPJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ6MUCxJO69VQ>?	NWLaWXdGW0GQR1XS
A172 cell	MlqzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUHqV5hQUW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTF3IN88US=>	NXfDS3p[W0GQR1XS
human BCPAP cell	MnnES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2LtPGlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI6QDd7IN88US=>	M{fJcXNCVkeHUh?=
human COLO-792 cell	M{fmNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTl5MjFOwG0>	NW\MV4hUW0GQR1XS
human DU-145 cell	Ml64S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWrXbm0{UW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjNzOEi5JO69VQ>?	MVPTRW5ITVJ?
NCI-H2122 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFTuUZVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlEzOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwM{KyPFUh\|ryP	NHz3UWlUSU6JRWK=
human SK-UT-1 cell	Mlf0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIrPPZNKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{OUWyJO69VQ>?	MWnTRW5ITVJ?
LXF-289 cell	M36zZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoT2TY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Ojl4NTFOwG0>	M2G3UHNCVkeHUh?=
human NCI-H1792 cell	NHO5[GZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mm[wTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN\|MEm2JO69VQ>?	MUHTRW5ITVJ?
MCF7 cell	M2HwVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn;UTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6zN\|I4PCEQvF2=	MnT6V2FPT0WU
HCT-15 cell	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4PqRWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzR\|MjFOwG0>	NFTjN41USU6JRWK=
human NCI-H358 cell	M1ftTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXLlR\|BtUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFM2QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwM{O1OVEh\|ryP	MVrTRW5ITVJ?
human HLE cell	NXK2bVlTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFTWUIFKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuN\|M4PTJizszN	MoflV2FPT0WU
human SW1088 cell	MoL5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3PCUGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Ozd7NzFOwG0>	MUnTRW5ITVJ?
human K5 cell	NUTNOnpFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWXBVZozUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuN\|YyPDlizszN	M{fVV3NCVkeHUh?=
human SR cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4O5bWlvcGmkaYTpc44hd2ZiaIXtZY4hW1JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO2OVcyKM7:TR?=	NWHhPZI1W0GQR1XS
human Calu-3 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEfMU4JKdmirYnn0bY9vKG:oIHj1cYFvKEOjbIWtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzZ6MkWg{txO	MkjwV2FPT0WU
human SK-MEL-30 cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NELENpFKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwM{m5NVMh\|ryP	NWqxdYtWW0GQR1XS
human SW780 cell	M37wd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGXy[YlKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTF2MjFOwG0>	NVLiT4RKW0GQR1XS
NCI-H1563 cell	NVHOSWpzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MonWTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzNEi0JO69VQ>?	MY\TRW5ITVJ?
human MKN45 cell	MnPTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIexb2tKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTl\|MTFOwG0>	NFrScppUSU6JRWK=
MDA-MB-157 cell	NUPqbZN3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnvaTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkCxOUDPxE1?	M3;tbXNCVkeHUh?=
human NCI-H522 cell	NYDpU\|lNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIC4c\|RKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkOg{txO	NX6zU5RtW0GQR1XS
human A2780 cell	NUHp[3hbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYjjSJpHUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDd3MEOg{txO	NWjzV\|lEW0GQR1XS
human A498 cell	NIjH[5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NInlWFZKdmirYnn0bY9vKG:oIHj1cYFvKEF2OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4Pjl\|IN88US=>	MnfmV2FPT0WU
human BxPC-3 cell	NHjPSWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH3MVlVKdmirYnn0bY9vKG:oIHj1cYFvKEK6UFOtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDl\|Nk[g{txO	NVTCe3gxW0GQR1XS
human A2058 cell	M17jZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3m4VGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzQDR2IN88US=>	MkDoV2FPT0WU
human PC-14 cell	M2DVbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYrJcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD61N\|g2PSEQvF2=	NGO0fGFUSU6JRWK=
human KG-1 cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2LFb2lvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOVU1OTlizszN	NW\GO2xuW0GQR1XS
human A375 cell	NFv3UWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1\FdmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOVYyODNizszN	MlLsV2FPT0WU
human SW1783 cell	NHHNcnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYPJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTd6MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|M{PyEQvF2=	MoXsV2FPT0WU
human MKN1 cell	NULmW3RiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWX2OWhEUW6qaXLpeIlwdiCxZjDoeY1idiCPS16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QDRzMjFOwG0>	MUDTRW5ITVJ?
NCI-H1650 cell	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4ftRmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OEmxOwOBiM7:TR?=	M1;oTnNCVkeHUh?=
human HT-1376 cell	Mo\1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2W4b2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUO3OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTJ7MUig{txO	Mne5V2FPT0WU
SW872 cell	M2TuU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkDGTY5pcWKrdHnvckBw\iCqdX3hckBUXzh5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuPVQ1PTlizszN	MlLwV2FPT0WU
human RT-112 cell	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVrFR4Y4UW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl5NEizJO69VQ>?	Mm\3V2FPT0WU
human HT-29 cell	M3XxUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVfJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD65O\|k6PiEQvF2=	NUD0dIt7W0GQR1XS
human U-266 cell	MlrDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGDSbHpKdmirYnn0bY9vKG:oIHj1cYFvKFVvMk[2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QDNyMjFOwG0>	M3\IOnNCVkeHUh?=
human HEL cell	M3zITGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmDqTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm4OVE4KM7:TR?=	Mn3JV2FPT0WU
human KU812 cell	NF3iOopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{fJSGlvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlEyOTZ2IN88US=>	MYTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-TYR / p-STAT5 / STAT5 / p-S6 / S6 / p-MAPK / MAPK / p-AKT / AKT ; PubMed: 28881711 Oncotarget Effect of midostaurin and PRT062607 on TEL-SYK phosphorylation and phosphorylation of downstream effectors following 2 hr of treatment. For the experiment analyzing effects of midostaurin and PRT062607 on phosphorylation of TEL-SYK, SYK immunoprecipitation was carried out prior to immunoblotting with a PTYR (4G10) antibody. Immunoblotting was performed for the experiment analyzing effects of midostaurin and PRT062607 on signaling molecules downstream of TEL-SYK. Relative densitometry readings for pMAPK/total MAPK (normalized to control lane) are as follows: 0 nM midostaurin=1.0, 10 nM midostaurin=0.93, 100 nM midostaurin=0.41, 1000 nM midostaurin=0.04, 0 nM PRT062607=1.0, 10 nM PRT062607=0.72, 100 nM PRT062607=0.37, 1000 nM PRT062607=0.07. PKCα / PKCβ1 / PKCβ2 / PKCγ / PKCη / p-PKC / p-Bad / Bad / p-Bcl2 / Bcl-2 / p-p65 / p65; PubMed: 30584254 Cell Death Dis The indicated PKC isoforms were up-regulated in the resistant BL cells, leading to elevated levels of PKC phosphorylation and the activation of downstream anti-apoptotic proteins.	28881711 30584254

In vivo

Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. ^[1]

Protocol

Cell Research:^[2]	- Collapse Cell lines: A549, NCI-H520 Concentrations: ~1.0 μM Incubation Time: 24-72 h Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Colo 205 colorectal tumors xenograft Dosages: 50 mg/kg, 200 mg/kg, once daily Administration: p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (175.24 mM)
	Water	Insoluble
	Ethanol	'20 mg/mL warmed
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Midostaurin (PKC412) SDF

Molecular Weight	570.64
Formula	C₃₅H₃₀N₄O₄
CAS No.	120685-11-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CGP 41251
Smiles	CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03951961	Not yet recruiting	Drug: Midostaurin	Acute Myeloid Leukemia Adult	Sebastian Scholl PD Dr. med.\|Ludwig-Maximilians - University of Munich\|University of Jena	May 1 2020	Phase 2
NCT04097470	Recruiting	Drug: Decitabine\|Drug: Midostaurin	AML/MDS	Stichting Hemato-Oncologie voor Volwassenen Nederland\|Swiss Group for Clinical Cancer Research	December 5 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PKC Signaling Pathway Map

Related PKC Products

SD-208 ^New

SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, >100-fold selectivity over TGF-βRII.
LDN-214117 ^New

LDN-214117 is a potent and selective BMP type I receptor kinase ALK2 inhibitor with IC50 of 24 nM.
Staurosporine

Staurosporine (CGP 41251) is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Sotrastaurin

Sotrastaurin (AEB071) is a potent and selective pan-PKC inhibitor, mostly for PKCθ with K_i of 0.22 nM in a cell-free assay; inactive to PKCζ. Phase 2.

Features:Unlike former PKC inhibitors, Sotrastaurin does not enhance apoptosis of murine T-cell blasts in a model of activation-induced cell death.
Go 6983

Go 6983 (GOE 6983) is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ and PKCδ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively; less potent to PKCζ and inactive to PKCμ.
Enzastaurin (LY317615)

Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM in cell-free assays, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3.
Bisindolylmaleimide I (GF109203X)

Bisindolylmaleimide I (GF109203X) is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ in cell-free assays, respectively, showing more than 3000-fold selectivity for PKC as compared to EGFR, PDGFR and insulin receptor.

Features:Greater selectivity than PKC inhibitor staurosporine. GF109203X is a chemical probe for studying PKC signal transduction pathways. Potential for use in a variety of cancers.
Go6976

Go6976 (PD406976) is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3.
Bisindolylmaleimide IX (Ro 31-8220 Mesylate)

Bisindolylmaleimide IX (Ro 31-8220 Mesylate) is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3β and S6K1.

Choose Your Country or Region

By Signaling Pathways

By product type

Midostaurin (PKC412)